BeStock  
Stocks › Biotechnology › URGN

UroGen Pharma Ltd URGN

US equityMarket cap rank #2953Biotechnology
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$89.00M+223.9% YoY
Operating profit$8.33M+130.4% YoY
Net profit-$1.46M+95.6% YoY
Diluted EPS-$0.03+95.7% YoY
Free cash flow-$15.27M+63.9% YoY
Operating cash flow-$15.20M

Revenue, last 8 quarters

$24.6MDec '24$20.3MMar '25$24.2MJun '25$27.5MSep '25$37.8MDec '25$51.0MMar '26$72.5MJun '26$89.0MSep '26

Net profit, last 8 quarters

$-37.5MDec '24$-43.8MMar '25$-49.9MJun '25$-33.3MSep '25$-26.4MDec '25$-23.6MMar '26$-14.4MJun '26$-1.5MSep '26

Diluted EPS by quarter

-0.80Dec '24-0.92Mar '25-1.05Jun '25-0.69Sep '25-0.54Dec '25-0.47Mar '26-0.28Jun '26-0.03Sep '26

Free cash flow by quarter

$-13.7MDec '24$-42.1MMar '25$-40.0MJun '25$-42.4MSep '25$-38.3MDec '25$-45.4MMar '26$-33.1MJun '26$-15.3MSep '26

Annual revenue

$11.8MFY20$48.0MFY21$64.4MFY22$82.7MFY23$90.4MFY24$109.8MFY25

Profitability & balance sheet

Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
Return on assets-28.8%
Current ratio3.40
Liabilities / assets146.1%
Cash & investments$90.55M
Total debt$194.12M
Net cash (debt)-$103.57M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Zusduri$68.04M 76.5%
  • Jelmyto$20.96M 23.5%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $89.00M $72.46M $50.96M $109.79M $37.84M
Total Operating Revenue $89.00M $72.46M $50.96M $109.79M $37.84M
Cost of Revenue $7.50M $6.57M $4.14M $12.45M $3.29M
Gross Profit $81.50M $65.88M $46.82M $97.34M $34.55M
Operating Expense $73.17M $65.77M $67.08M $222.20M $53.66M
Selling and Admin Expenses $47.21M $48.44M $51.49M $155.10M $39.35M
Research & Development $25.96M $17.34M $15.60M $67.11M $14.31M
Operating Profit $8.33M $111,000.00 -$20.26M -$124.86M -$19.12M
Net Non-Operating Interest Income (Expense) -$8.70M -$8.49M -$7.76M -$27.88M -$7.52M
Non-Operating Interest Income $681,000.00 $946,000.00 $931,000.00 $5.97M $908,000.00
Non-Operating Interest Expense $4.84M $4.89M $4.19M $15.35M $3.77M
Total Other Finance Costs $4.55M $4.55M $4.51M $18.50M $4.66M
Other Income (Expense) -$74,000.00 -$347,000.00 -$323,000.00 -$670,000.00 -$5,000.00
Other Non-Operating Income (Expenses) -$74,000.00 -$347,000.00 -$323,000.00 -$670,000.00 -$5,000.00
Pretax Profit -$446,000.00 -$8.72M -$28.35M -$153.42M -$26.64M
Tax $1.02M $5.63M -$4.77M $78,000.00 -$275,000.00
Net Profit -$1.46M -$14.35M -$23.57M -$153.49M -$26.36M
Profit from Continuing Operations -$1.46M -$14.35M -$23.57M -$153.49M -$26.36M
Net Income to Parent Company -$1.46M -$14.35M -$23.57M -$153.49M -$26.36M
Net Income to Common Stockholders -$1.46M -$14.35M -$23.57M -$153.49M -$26.36M
Basic EPS -$0.03 -$0.28 -$0.47 -$3.19 -$0.54
Diluted EPS -$0.03 -$0.28 -$0.47 -$3.19 -$0.54

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $271.87M $252.59M $253.69M $200.46M $200.46M
Total Current Assets $251.90M $235.43M $237.46M $186.02M $186.02M
Cash and Cash Equivalents & Short-Term Investments $90.55M $107.98M $140.27M $120.46M $120.46M
-Cash and Cash Equivalents $85.56M $79.13M $109.97M $110.75M $110.75M
-Short Term Investments $4.99M $28.84M $30.31M $9.71M $9.71M
Receivables $117.28M $88.76M $55.41M $33.08M $33.08M
-Accounts Receivable $117.28M $88.76M $55.41M $33.08M $33.08M
Inventory $25.15M $24.59M $20.92M $16.46M $16.46M
Restricted Cash $1.33M $1.33M $1.33M $1.35M $1.35M
Other Current Assets $17.58M $12.78M $19.53M $14.67M $14.67M
Total Non-Current Assets $19.98M $17.16M $16.23M $14.43M $14.43M
Net PPE $7.94M $8.23M $8.56M $9.09M $9.09M
-Gross PPE $12.76M $12.97M $13.22M $13.68M $13.68M
-Accumulated Depreciation -$4.82M -$4.74M -$4.66M -$4.59M -$4.59M
Other Non-Current Assets $12.04M $8.94M $7.67M $5.34M $5.34M
Total Liabilities $397.09M $384.99M $377.94M $305.93M $305.93M
Total Current Liabilities $74.03M $61.92M $50.64M $46.42M $46.42M
Payables $17.26M $15.47M $17.21M $12.14M $12.14M
-Accounts Payable $17.26M $15.47M $17.21M $12.14M $12.14M
Current Accrued Expenses $29.58M $24.47M $18.14M $15.58M $15.58M
Short-Term Debt and Capital Lease Obligation $2.16M $2.10M – – –
-Current Capital Lease Obligation $2.16M $2.10M – – –
Other Current Liabilities $8.14M $7.62M $5.45M $5.19M $5.19M
Total Non-Current Liabilities $323.06M $323.07M $327.31M $259.51M $259.51M
Long Term Accounts Payable and Other Payables $3.90M $3.90M $3.90M $3.90M $3.90M
Long Term Debt and Capital Lease Obligation $194.12M $194.03M $195.18M $128.33M $128.33M
-Long Term Debt $189.35M $188.73M $189.53M $122.21M $122.21M
-Long Term Capital Lease Obligation $4.77M $5.30M $5.65M $6.12M $6.12M
Derivative Product Liabilities $125.03M $125.14M $128.23M $127.28M $127.28M
Total Equity -$125.22M -$132.40M -$124.25M -$105.47M -$105.47M
Stockholders' Equity -$125.22M -$132.40M -$124.25M -$105.47M -$105.47M
Capital Stock $135,000.00 $135,000.00 $134,000.00 $133,000.00 $133,000.00
-Common Stock $135,000.00 $135,000.00 $134,000.00 $133,000.00 $133,000.00
Additional Paid-In Capital $873.75M $865.11M $858.90M $854.09M $854.09M
Retained Earnings -$999.10M -$997.64M -$983.29M -$959.72M -$959.72M
Gains/Losses Not Affecting Retained Earnings -$1,000.00 -$2,000.00 $8,000.00 $19,000.00 $19,000.00
Investments and Advances – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$15.20M -$33.01M -$45.32M -$162.44M -$38.33M
Net cash flow from continuing operations -$15.20M -$33.01M -$45.32M -$162.44M -$38.33M
Net Income from Continuing Operations -$1.46M -$14.35M -$23.57M -$153.49M -$26.36M
Gain/Loss from Continuing Operations $423,000.00 $991,000.00 $1.06M $2.87M $1.27M
Depreciation & Depletion & Amortization $694,000.00 $668,000.00 $652,000.00 $2.41M $679,000.00
Other Non-Cash Items $620,000.00 -$796,000.00 $1.97M $3.60M $99,000.00
Change in Working Capital -$21.65M -$24.57M -$30.08M -$27.91M -$17.06M
-Change in Receivables -$28.53M -$33.35M -$22.33M -$12.78M -$13.38M
-Change in Inventory -$561,000.00 -$3.67M -$4.46M -$7.24M -$8.12M
-Change in Prepaid Assets -$4.81M $6.75M -$4.86M -$5.83M -$2.55M
-Change in Payables and Accrued Expense $11.53M $7.02M $3.95M $3.23M $3.95M
-Change in Other Current Assets $904,000.00 -$1.27M -$2.33M -$4.57M $1.60M
-Change in Other Current Liabilities -$190,000.00 -$60,000.00 -$53,000.00 -$729,000.00 $1.44M
-Change In Other Working Capital $0.00 – – -$1,000.00 $0.00
Net cash flow from investing $19.85M $1.67M -$20.69M $61.56M $27.72M
Net Cash Flow from Continuing Investing Activities $19.85M $1.67M -$20.69M $61.56M $27.72M
Net PPE Purchase and Sale -$72,000.00 -$60,000.00 -$54,000.00 -$289,000.00 -$17,000.00
Net Investment Purchase and Sale $19.93M $1.73M -$20.63M $61.85M $27.73M
Financing Cash Flow $1.78M $500,000.00 $65.20M $39.92M $31.32M
Net Cash Flow from Continuing Financing Activities $1.78M $500,000.00 $65.20M $39.92M $31.32M
Net Issuance Payments Of Debt -$616,000.00 -$387,000.00 $65.03M -$1.86M -$1.86M
Proceeds from Stock Option Exercised $2.39M $887,000.00 $179,000.00 $1.97M $1.34M
Ending Cash Balance $86.90M $80.46M $111.30M $112.10M $112.10M
Net Change in Cash $6.43M -$30.83M -$800,000.00 -$60.97M $20.71M
Beginning Cash Balance $80.46M $111.30M $112.10M $173.06M $91.39M
Free Cash Flow -$15.27M -$33.07M -$45.37M -$162.73M -$38.34M
Net Common Stock Issuance – – $0.00 $39.80M $31.83M

Discussion

No comments yet — be the first to weigh in on URGN.

Sign in to join the discussion.

Scroll to Top